Pfizer Abandons Obesity Pill After Trial Liver Injury
2025-04-14 14:06
https://finance.yahoo.com/video/pfizer-abandons-obesity-pill-trial-140656016.html?.tsrc=rss
Oops, something went wrongTip: Try a valid symbol or a specific company name for relevant resultsOops, something went wrongTrump is wrecking his own economic agendaHigher clothing costs from tariffs are coming soon — but not immediately, experts sayWhy Tesla, GM, and Rivian will be hurt most by China's critical minerals export banTrump says he's 'looking at something' to help car companies with tariffsStocks rally for second straight day, while Apple jumps on tech tariff reprieveThe Nasdaq briefly turned red as stocks' relief rally failed to hold in early afternoon tradingAmericans are braced for the biggest unemployment rate jump since the pandemic, a New York Fed survey foundStocks surge as Apple leads way higher after tech's tariff reprieveTrump's temporary tech tariff respite adds to a growing sense that he has a willingness to listen and bendGoldman CEO Solomon warns of 'markedly different operating environment' as dealmaking slowsCorporate earnings take center stage amid tariff turmoil: What to know this weekTrump has tariffs, taxes, and the debt ceiling on a collision course for this summerTrump denies that there was a tariff “exception” for certain electronics announced Friday. (Bloomberg)Tax day 2025 is coming up. Here’s what to know to file by the deadline.Commentary: Put the P/E ratio in timeout for nowMarket chaos signals 'sell America' trade as Trump tariff whipsaw threatens to upend the US economy's soft landingApple was on brink of crisis before tariff concession from Trump (Bloomberg)Corporate earnings take center stage amid tariff turmoil: What to know this weekThe best (and worst) time of year to buy a houseThe Trump family is going all-in on crypto projects, from Bitcoin mining to stablecoins (Bloomberg)How to invest in gold in 4 stepsChanging jobs can disrupt saving for retirement. Here's how to stay on track.Trump exempts phones, computers, chips from ‘reciprocal’ tariffs (Bloomberg)Meet Walmart heir Steuart Walton, the most powerful board member you’ve never heard ofThe tariff uncertainty isn't getting any better in markets: Chart of the Week'T-shirts could be the new eggs': Why Trump's chaotic tariff whipsaw is still a huge threat to inflationGold notches best week since 2020 amid 'shaken' investor confidence in USThe bond market just had one of its most volatile and unusual weeks in recent memoryStocks capped a wild week with a surge higher, as the S&P 500 posted its biggest weekly gain since 2023Stocks swung into rally mode in afternoon trading, with the major indexes all up over 1%. Bond yields pared bigger gains.The major indexes whipsawed to end a volatile week. Treasury yields surged in signs of more instability in the bond market.Consumer sentiment craters further as inflation expectations soar to highest since 1981Dow, S&P 500, Nasdaq slide as China hits US with tariff hike, bank earnings roll inJPMorgan's Dimon says economy is facing 'considerable turbulence'Tariff uncertainty muddies — and refocuses — earnings seasonChina raises tariffs on US goods to 125% from the 84% planned in response to Trump's latest hikeChina already knows Trump's breaking point in their burgeoning trade war, our columnist writesHow the bond market helped make Trump blink on tariffsThe Dow fell 1,000 points, and the S&P 500 and Nasdaq were crushed as stocks resumed a tariff-fueled sell-offTrump's total tariff on China is actually 145%, the White House said, an amount higher than the 125% previously reportedStocks hit session lows as focus turned to the US-China trade war. The Dow lost over 1,200 points, and the Nasdaq plunged 4.5%.The Dow plummeted 900 points and the Nasdaq plunged over 3% as a tariff-fueled sell-off picked up speed again.Stocks plummet as Wall Street's euphoria from Trump's tariff pause gets a reality checkInflation unexpectedly tumbled in March, and core CPI rose at its slowest pace in four years.The EU matched Trump's 90-day pause on tariffs to 'give negtiations a chance.' See our live updates.The 'Trump put' makes an appearanceMarch's report could be last time investors see inflation easing. Here's what to expect.Stocks wanted one thing from Trump after his shocking tariff announcement last week. They finally got it today.Stocks staged a wild rally after Trump's tariff reversal. The Dow gained near 3,000 points and the S&P 500 had its best day since 2008.Trump nodded to market turbulence as a factor in his 'reciprocal' tariff pause, saying investors were 'yippy' and 'afraid'Unlock stock picks and a broker-level newsfeed that powers Wall Street.Pfizer Inc. will stop developing an obesity pill after the treatment was linked to a potentially drug-related liver injury in a clinical trial patient. The company won't advance the once-daily medicine into the final stage of testing and will instead invest in earlier-stage treatments for obesity. Damian Garde reports on Bloomberg Television.Pfizer  is halting development of its experimental weight-loss pill, as the booming obesity drug market remains out of reach for the drug giant.  The company said Monday the stoppage comes after it reviewed clinical data and a study subject developed a liver injury that might have been caused by the drug, called danuglipron.  Halting the drug’s development means  Pfizer  still is unable to get a cut, for now, of the white-hot obesity market, which analysts say could reach $100 billion by the end of the decade.Pfizer (PFE) announced Monday that it is ending development of its daily weight-loss pill following a liver injury to a patient participating in a trial.Commerce Secretary Howard Lutnick told ABC News the upcoming tariffs for electronics are based on Section 232, which allows President Trump to adjust imports that pose a threat to national security.The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.Find insight on Pfizer, Roche, Monash IVF, and more in the latest Market Talks covering the Health Care sector.Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing.  The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a possible drug-induced liver injury that ended once the person stopped taking the treatment.  The once-daily version of the pill was in early-stage testing, with researchers trying to figure out the best dose for patients, a spokeswoman said.Viking Therapeutics stock rocketed Monday after Pfizer said it's scrapping development of its daily weight-loss pill.Pfizer still has another obesity pill in development, PF-07976016, which is currently in a Phase IIa trial.We recently published a list of 10 Best Kid-Friendly Stocks to Buy According to Billionaires. In this article, we are going to take a look at where The Walt Disney Company (NYSE:DIS) stands against other best kid-friendly stocks to buy according to billionaires. The market has been undergoing a volatile spell these past few days. […]Does JPM stock deserve a place in your investment portfolio after posting an upbeat Q1 performance? Let's find out.Tip: Try a valid symbol or a specific company name for relevant resultsSign in to access your portfolioTry again.